PremiumThe FlyImmunityBio receives FDA Expanded Access authorization for Cancer BioShield ImmunityBio to launch Cancer BioShield in the Middle East Piper upgrades ImmunityBio on Anktiva expansion opportunities PremiumThe FlyImmunityBio reports Q1 EPS (15c), consensus (14c) Biotech Alert: Searches spiking for these stocks today Largest borrow rate increases among liquid names PremiumThe FlyImmunityBio announces long-term results from QUILT-3.032 study Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge ImmunityBio’s Promising Advances in Cancer Treatment Bolster Buy Rating 
